Breaking News Headlines Today | Ground News

See every side of every news story

targetedonc.com image

News from targetedonc.com

See all of targetedonc.com’s headline news. Compare how the top news stories are covered by left-wing and right-wing news sources.

We’ve aggregated 706 of targetedonc.com’s headlines and news stories over the past 3 months.

Ground News rates targetedonc.com’s media bias as unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is targetedonc.com credible or reliable? Our Factuality score answers both of those questions. When it comes to targetedonc.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about targetedonc.com

Where is targetedonc.com located?targetedonc.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top targetedonc.com News

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer

Cancer · United States

U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics' ADRX-0405 STEAP1 ADC for Gastric Cancer

94% Center coverage: 16 sources

Orphan drug designation highlights the potential for ADRX-0405 to address the high unmet need in gastric cancer See the Story

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

Cancer · United States

Exact Sciences Announces Medicare Coverage for Oncodetect™ Molecular Residual Disease Test in Colorectal Cancer

60% Center coverage: 5 sources

MADISON, Wis.--(BUSINESS WIRE)--Jul 9, 2025-See the Story

Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

United States · United States

Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma

100% Center coverage: 1 sources

/PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology solutions, today announced that the U.S. Food and Drug...See the Story

IASO Bio Receives Orphan Drug Designation From the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

SHANGHAI, NANJING, China and SAN FRANCISCO, July 9, 2025 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that its self-developed anti-BCMA CAR-T cell therapy product, Equecabtagene Autoleucel (Fucaso), has been granted Orphan Drug Designation (ODD) by the Ministry of Food and Drug S…See the Story

FDA Grants Orphan Drug Designation to FF-10832 in Biliary Tract Cancer

The liposomal formulation of gemcitabine may enhance anti-tumor activity by increasing plasma half-life and improving targeted delivery to tumors.United States · United States See the Story

Newer Approaches Show Potential to Reduce Need for Transplant in NDMM

During a live event, Hans Lee, MD, and participants shared their perspectives on current and upcoming treatment approaches in transplant-eligible multiple myeloma.Maryland · Maryland Read Article

Venetoclax Consolidation After BTKi Shows Promise in CLL

A study reveals that venetoclax consolidation after BTKi therapy is effective for chronic lymphocytic leukemia, offering promising outcomes for patients.Read Article

Monotherapy Shows Promise in ET and MF as Trials Advance Globally

Early data show promising platelet and molecular responses with monoclonal antibody monotherapy in ET and MF, with trials ongoing in the US and abroad.United States · United States Read Article

A New Era in Myeloma: An Interview with Elena Zamagni

In the beginning, when I was very young, I was more interested in acute leukaemia and the suffering of young people. When I got to...See the Story

FDA Draft Guidance Illuminates MDS Drug Development Pathways

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.United States · United States Read Article

Dr Spigel Covers the AIM-HIGH Trial in Early NSCLC

David Spigel, MD, discusses the pivotal findings from the AIM-HIGH trial in early-stage non-squamous NSCLC.Maryland · Maryland Read Article

Breaking News Topics Related to targetedonc.com